Aktis Oncology (AKTS) Competitors

$19.28 +0.28 (+1.47%)

As of 03:30 PM Eastern

AKTS vs. INDV, CRNX, NNNN, AMRX, and ORKA

Should you be buying Aktis Oncology stock or one of its competitors? The main competitors of Aktis Oncology include Indivior (INDV), Crinetics Pharmaceuticals (CRNX), Anbio Biotechnology (NNNN), Amneal Pharmaceuticals (AMRX), and Oruka Therapeutics (ORKA). These companies are all part of the "pharmaceutical products" industry.

How does Aktis Oncology compare to Indivior?

Indivior (NASDAQ:INDV) and Aktis Oncology (NASDAQ:AKTS) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

: In the previous week, Indivior had 13 more articles in the media than Aktis Oncology. MarketBeat recorded 20 mentions for Indivior and 7 mentions for Aktis Oncology. Indivior's average media sentiment score of 0.81 beat Aktis Oncology's score of 0.17 indicating that Indivior is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Indivior
4 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Aktis Oncology
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
: Indivior presently has a consensus target price of $39.33, suggesting a potential upside of 0.50%. Aktis Oncology has a consensus target price of $32.00, suggesting a potential upside of 65.98%. Given Aktis Oncology's higher possible upside, analysts plainly believe Aktis Oncology is more favorable than Indivior.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Indivior
0 Sell rating(s)
1 Hold rating(s)

5 Buy rating(s)

1 Strong Buy rating(s)
3.00
Aktis Oncology
0 Sell rating(s)

0 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
3.00
: 60.3% of Indivior shares are owned by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are owned by institutional investors. 0.7% of Indivior shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
: Indivior has higher revenue and earnings than Aktis Oncology.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Indivior $1.24B 3.85 $210M $1.95 20.07
Aktis Oncology $6.50M 158.39 N/A N/A N/A
: Indivior has a net margin of 19.44% compared to Aktis Oncology's net margin of 0.00%. Aktis Oncology's return on equity of 0.00% beat Indivior's return on equity.
Company Net Margins Return on Equity Return on Assets
Indivior 19.44% -219.26% 29.40%
Aktis Oncology N/A N/A N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Aktis Oncology	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Aktis Oncology	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.85	$210M	$1.95	20.07
Aktis Oncology	$6.50M	158.39	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Indivior	19.44%	-219.26%	29.40%
Aktis Oncology	N/A	N/A	N/A

Summary

Indivior beats Aktis Oncology on 8 of the 12 factors compared between the two stocks.

How does Aktis Oncology compare to Crinetics Pharmaceuticals?

Aktis Oncology (NASDAQ:AKTS) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

: Aktis Oncology has higher earnings, but lower revenue than Crinetics Pharmaceuticals.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aktis Oncology $6.50M 158.39 N/A N/A N/A
Crinetics Pharmaceuticals $7.70M 557.86 -$465.32M -$4.94 N/A
: Aktis Oncology has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -6,046.22%. Aktis Oncology's return on equity of 0.00% beat Crinetics Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Aktis Oncology N/A N/A N/A
Crinetics Pharmaceuticals -6,046.22% -41.46% -37.43%
: Aktis Oncology presently has a consensus target price of $32.00, suggesting a potential upside of 65.98%. Crinetics Pharmaceuticals has a consensus target price of $76.75, suggesting a potential upside of 88.49%. Given Crinetics Pharmaceuticals' higher probable upside, analysts plainly believe Crinetics Pharmaceuticals is more favorable than Aktis Oncology.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aktis Oncology
0 Sell rating(s)
0 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
3.00
Crinetics Pharmaceuticals
1 Sell rating(s)

0 Hold rating(s)

8 Buy rating(s)

1 Strong Buy rating(s)
2.90
: In the previous week, Crinetics Pharmaceuticals had 5 more articles in the media than Aktis Oncology. MarketBeat recorded 12 mentions for Crinetics Pharmaceuticals and 7 mentions for Aktis Oncology. Crinetics Pharmaceuticals' average media sentiment score of 0.96 beat Aktis Oncology's score of 0.17 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aktis Oncology
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Crinetics Pharmaceuticals
5 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: 28.8% of Aktis Oncology shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 6.0% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	158.39	N/A	N/A	N/A
Crinetics Pharmaceuticals	$7.70M	557.86	-$465.32M	-$4.94	N/A

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Crinetics Pharmaceuticals	-6,046.22%	-41.46%	-37.43%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Crinetics Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Crinetics Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Crinetics Pharmaceuticals beats Aktis Oncology on 9 of the 13 factors compared between the two stocks.

How does Aktis Oncology compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and Aktis Oncology (NASDAQ:AKTS) are both manufacturing companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

: 28.8% of Aktis Oncology shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
: Company Net Margins Return on Equity Return on Assets
Anbio Biotechnology N/A N/A N/A
Aktis Oncology N/A N/A N/A
: In the previous week, Aktis Oncology had 6 more articles in the media than Anbio Biotechnology. MarketBeat recorded 7 mentions for Aktis Oncology and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 0.64 beat Aktis Oncology's score of 0.17 indicating that Anbio Biotechnology is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Anbio Biotechnology
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aktis Oncology
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
: Anbio Biotechnology has higher revenue and earnings than Aktis Oncology.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Anbio Biotechnology $8.65M 490.91 $6.40M N/A N/A
Aktis Oncology $6.50M 158.39 N/A N/A N/A
: Aktis Oncology has a consensus target price of $32.00, suggesting a potential upside of 65.98%. Given Aktis Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Aktis Oncology is more favorable than Anbio Biotechnology.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anbio Biotechnology
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Aktis Oncology
0 Sell rating(s)

0 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
3.00

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Aktis Oncology	N/A	N/A	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anbio Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aktis Oncology	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	490.91	$6.40M	N/A	N/A
Aktis Oncology	$6.50M	158.39	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aktis Oncology	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Aktis Oncology beats Anbio Biotechnology on 5 of the 8 factors compared between the two stocks.

How does Aktis Oncology compare to Amneal Pharmaceuticals?

Aktis Oncology (NASDAQ:AKTS) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

: 28.8% of Aktis Oncology shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
: Aktis Oncology presently has a consensus target price of $32.00, indicating a potential upside of 65.98%. Amneal Pharmaceuticals has a consensus target price of $15.00, indicating a potential upside of 11.90%. Given Aktis Oncology's stronger consensus rating and higher probable upside, research analysts clearly believe Aktis Oncology is more favorable than Amneal Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aktis Oncology
0 Sell rating(s)
0 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
3.00
Amneal Pharmaceuticals
0 Sell rating(s)

2 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.75
: In the previous week, Aktis Oncology and Aktis Oncology both had 7 articles in the media. Amneal Pharmaceuticals' average media sentiment score of 0.75 beat Aktis Oncology's score of 0.17 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aktis Oncology
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Amneal Pharmaceuticals
3 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Amneal Pharmaceuticals has higher revenue and earnings than Aktis Oncology.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aktis Oncology $6.50M 158.39 N/A N/A N/A
Amneal Pharmaceuticals $3.02B 1.40 $72.06M $0.38 35.28
: Amneal Pharmaceuticals has a net margin of 4.53% compared to Aktis Oncology's net margin of 0.00%. Aktis Oncology's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Aktis Oncology N/A N/A N/A
Amneal Pharmaceuticals 4.53% -276.67% 7.60%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Amneal Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	158.39	N/A	N/A	N/A
Amneal Pharmaceuticals	$3.02B	1.40	$72.06M	$0.38	35.28

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Amneal Pharmaceuticals	4.53%	-276.67%	7.60%

Summary

Amneal Pharmaceuticals beats Aktis Oncology on 6 of the 10 factors compared between the two stocks.

How does Aktis Oncology compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Aktis Oncology (NASDAQ:AKTS) are both pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

: Oruka Therapeutics currently has a consensus target price of $120.80, suggesting a potential upside of 78.59%. Aktis Oncology has a consensus target price of $32.00, suggesting a potential upside of 65.98%. Given Oruka Therapeutics' higher possible upside, analysts clearly believe Oruka Therapeutics is more favorable than Aktis Oncology.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oruka Therapeutics
1 Sell rating(s)
0 Hold rating(s)

10 Buy rating(s)

0 Strong Buy rating(s)
2.82
Aktis Oncology
0 Sell rating(s)

0 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
3.00
: Aktis Oncology's return on equity of 0.00% beat Oruka Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Oruka Therapeutics N/A -25.48% -24.34%
Aktis Oncology N/A N/A N/A
: Aktis Oncology has higher revenue and earnings than Oruka Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Oruka Therapeutics N/A N/A -$105.43M -$1.86 N/A
Aktis Oncology $6.50M 158.39 N/A N/A N/A
: In the previous week, Oruka Therapeutics had 16 more articles in the media than Aktis Oncology. MarketBeat recorded 23 mentions for Oruka Therapeutics and 7 mentions for Aktis Oncology. Oruka Therapeutics' average media sentiment score of 0.74 beat Aktis Oncology's score of 0.17 indicating that Oruka Therapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oruka Therapeutics
7 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Aktis Oncology
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
: 56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are owned by institutional investors. 24.7% of Oruka Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Aktis Oncology	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-25.48%	-24.34%
Aktis Oncology	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.86	N/A
Aktis Oncology	$6.50M	158.39	N/A	N/A	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Aktis Oncology	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Oruka Therapeutics beats Aktis Oncology on 6 of the 10 factors compared between the two stocks.

Get Aktis Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AKTS vs. The Competition

Export

Metric	Aktis Oncology	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.03B	$2.90B	$4.21B	$11.87B
Dividend Yield	N/A	15.26%	5.61%	5.21%
P/E Ratio	N/A	13.17	23.39	28.47
Price / Sales	158.39	1,690.30	188.18	61.65
Price / Cash	N/A	25.75	52.82	36.52
Price / Book	N/A	3.55	38.30	6.67
Net Income	N/A	-$42.77M	$114.66M	$332.53M
7 Day Performance	3.66%	1.10%	1.31%	1.98%
1 Month Performance	11.00%	5.43%	5.65%	9.14%
1 Year Performance	N/A	19.89%	18.75%	39.55%

Aktis Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AKTS Aktis Oncology	1.7778 of 5 stars	$19.28 +1.5%	$32.00 +66.0%	N/A	$1.03B	$6.50M	N/A	76	News Coverage Upcoming Earnings
INDV Indivior	2.8111 of 5 stars	$34.31 +3.3%	$39.33 +14.6%	N/A	$4.18B	$1.24B	20.92	1,051	News Coverage Earnings Report Analyst Revision
CRNX Crinetics Pharmaceuticals	3.3368 of 5 stars	$38.62 +0.8%	$76.63 +98.4%	N/A	$4.04B	$7.70M	N/A	210	Positive News Upcoming Earnings Gap Up
NNNN Anbio Biotechnology	N/A	$27.65 +1.1%	N/A	N/A	$3.98B	$8.65M	N/A	27	News Coverage Positive News Gap Down
AMRX Amneal Pharmaceuticals	3.0724 of 5 stars	$12.57 +0.4%	$15.00 +19.3%	N/A	$3.95B	$3.02B	33.08	8,500

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AKTS) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aktis Oncology (AKTS) Competitors

AKTS vs. INDV, CRNX, NNNN, AMRX, and ORKA

How does Aktis Oncology compare to Indivior?

Summary

How does Aktis Oncology compare to Crinetics Pharmaceuticals?

Summary

How does Aktis Oncology compare to Anbio Biotechnology?

Summary

How does Aktis Oncology compare to Amneal Pharmaceuticals?

Summary

How does Aktis Oncology compare to Oruka Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTS vs. The Competition

Aktis Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aktis Oncology (AKTS) Competitors

AKTS vs. INDV, CRNX, NNNN, AMRX, and ORKA

How does Aktis Oncology compare to Indivior?

Summary

How does Aktis Oncology compare to Crinetics Pharmaceuticals?

Summary

How does Aktis Oncology compare to Anbio Biotechnology?

Summary

How does Aktis Oncology compare to Amneal Pharmaceuticals?

Summary

How does Aktis Oncology compare to Oruka Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTS vs. The Competition

Aktis Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools